Latanoprost for Treatment of Ménière Disease : A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy of Intratympanic Management for Symptom Control
(2026) In Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 47(2). p.328-335- Abstract
OBJECTIVE: A previous placebo-controlled crossover study of intratympanic latanoprost-a drug commonly used for glaucoma treatment-showed positive effects on hearing, tinnitus, and vertigo in patients with long-standing Ménière disease (MD). We aimed to test the safety and efficacy of intratympanic treatment with latanoprost 0.0005% versus placebo in patients with active MD concerning speech discrimination in noise, hearing, tinnitus, and vertigo. STUDY DESIGN: A prospective, randomized, double-blind, placebo-controlled study over 3 months in patients with active stage II to III MD. SETTING: Twelve otolaryngology referral centers across Sweden. INTERVENTION: Patients were allocated to intratympanic injection of latanoprost 0.0005%... (More)
OBJECTIVE: A previous placebo-controlled crossover study of intratympanic latanoprost-a drug commonly used for glaucoma treatment-showed positive effects on hearing, tinnitus, and vertigo in patients with long-standing Ménière disease (MD). We aimed to test the safety and efficacy of intratympanic treatment with latanoprost 0.0005% versus placebo in patients with active MD concerning speech discrimination in noise, hearing, tinnitus, and vertigo. STUDY DESIGN: A prospective, randomized, double-blind, placebo-controlled study over 3 months in patients with active stage II to III MD. SETTING: Twelve otolaryngology referral centers across Sweden. INTERVENTION: Patients were allocated to intratympanic injection of latanoprost 0.0005% administered as a single injection on day 1, or 3 injections over 3 consecutive days, or placebo administered as a single injection or 3 injections over 3 consecutive days. MAIN OUTCOME MEASURES: The primary outcome was change in speech discrimination in noise, assessed using phonetically balanced monosyllabic Swedish words (PB S/N+4dB), from baseline (day 1) to day 14. Secondary outcomes were change in pure tone average measured at 0.25, 0.5, 1, 2, 3, 4, 6, and 8 kHz, tinnitus according to the Tinnitus Handicap Inventory (THI) score and vertigo measured at 2, 4, 6, and 8 weeks after the first injection. Hearing, tinnitus, and vertigo were also assessed according to a Likert scale scored from 0 to 10. Days with vertigo attacks lasting ≥20 minutes were registered twice a week by patients. LS means were compared for each outcome measure. RESULTS: When comparing latanoprost (1 or 3 injections) with placebo (1 or 3 injections), no statistically significant difference was seen for the change in speech discrimination in noise from baseline to day 14, 0.4 (95% CI: -4.5; 5.3), P =0.88. None of the secondary efficacy measures showed a statistically significant difference between latanoprost and placebo. Latanoprost treatment was well tolerated. CONCLUSIONS: In this placebo-controlled study, latanoprost was not more effective than placebo in the treatment of MD and did not improve speech discrimination in noise, hearing, and tinnitus or vertigo symptoms.
(Less)
- author
- Lindell, Ellen ; Tomanovic, Tatjana ; Dahlin Redfors, Ylva ; Engmér Berglin, Cecilia and Karlberg, Mikael LU
- organization
- publishing date
- 2026-02-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Intratympanic treatment, Latanoprost, Meniere disease, RCT, Speech discrimination in noice
- in
- Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
- volume
- 47
- issue
- 2
- pages
- 8 pages
- publisher
- Lippincott Williams & Wilkins
- external identifiers
-
- pmid:41324607
- scopus:105027099549
- ISSN
- 1537-4505
- DOI
- 10.1097/MAO.0000000000004732
- language
- English
- LU publication?
- yes
- additional info
- Publisher Copyright: Copyright © 2025, Otology & Neurotology, Inc.
- id
- fe27795b-1cef-434a-a965-eb7d90b31b7c
- date added to LUP
- 2026-03-09 13:39:43
- date last changed
- 2026-05-19 01:10:32
@article{fe27795b-1cef-434a-a965-eb7d90b31b7c,
abstract = {{<p>OBJECTIVE: A previous placebo-controlled crossover study of intratympanic latanoprost-a drug commonly used for glaucoma treatment-showed positive effects on hearing, tinnitus, and vertigo in patients with long-standing Ménière disease (MD). We aimed to test the safety and efficacy of intratympanic treatment with latanoprost 0.0005% versus placebo in patients with active MD concerning speech discrimination in noise, hearing, tinnitus, and vertigo. STUDY DESIGN: A prospective, randomized, double-blind, placebo-controlled study over 3 months in patients with active stage II to III MD. SETTING: Twelve otolaryngology referral centers across Sweden. INTERVENTION: Patients were allocated to intratympanic injection of latanoprost 0.0005% administered as a single injection on day 1, or 3 injections over 3 consecutive days, or placebo administered as a single injection or 3 injections over 3 consecutive days. MAIN OUTCOME MEASURES: The primary outcome was change in speech discrimination in noise, assessed using phonetically balanced monosyllabic Swedish words (PB S/N+4dB), from baseline (day 1) to day 14. Secondary outcomes were change in pure tone average measured at 0.25, 0.5, 1, 2, 3, 4, 6, and 8 kHz, tinnitus according to the Tinnitus Handicap Inventory (THI) score and vertigo measured at 2, 4, 6, and 8 weeks after the first injection. Hearing, tinnitus, and vertigo were also assessed according to a Likert scale scored from 0 to 10. Days with vertigo attacks lasting ≥20 minutes were registered twice a week by patients. LS means were compared for each outcome measure. RESULTS: When comparing latanoprost (1 or 3 injections) with placebo (1 or 3 injections), no statistically significant difference was seen for the change in speech discrimination in noise from baseline to day 14, 0.4 (95% CI: -4.5; 5.3), P =0.88. None of the secondary efficacy measures showed a statistically significant difference between latanoprost and placebo. Latanoprost treatment was well tolerated. CONCLUSIONS: In this placebo-controlled study, latanoprost was not more effective than placebo in the treatment of MD and did not improve speech discrimination in noise, hearing, and tinnitus or vertigo symptoms.</p>}},
author = {{Lindell, Ellen and Tomanovic, Tatjana and Dahlin Redfors, Ylva and Engmér Berglin, Cecilia and Karlberg, Mikael}},
issn = {{1537-4505}},
keywords = {{Intratympanic treatment; Latanoprost; Meniere disease; RCT; Speech discrimination in noice}},
language = {{eng}},
month = {{02}},
number = {{2}},
pages = {{328--335}},
publisher = {{Lippincott Williams & Wilkins}},
series = {{Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology}},
title = {{Latanoprost for Treatment of Ménière Disease : A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy of Intratympanic Management for Symptom Control}},
url = {{http://dx.doi.org/10.1097/MAO.0000000000004732}},
doi = {{10.1097/MAO.0000000000004732}},
volume = {{47}},
year = {{2026}},
}